Interstitial cystitis

Confirming the Disease Name

Interstitial cystitis (Interstitial Cystitis) — This is the medically accepted term for a condition primarily characterized by chronic bladder pain and urinary symptoms (such as urinary frequency, nocturia, and urgency).

---

1) Disease Description (Causes and Symptoms)

• Causes and pathophysiology
  • No single definitive cause is known.
  • Proposed mechanisms include: increased permeability due to defects in the bladder epithelium (especially the GAG layer) → irritation of the bladder wall by urinary components, neurogenic inflammation, autoimmune mechanisms, and other combined factors.
  • It is more common in women (women comprise the majority of patients) and generally follows a chronic course.
• Main symptoms
  • A feeling of bladder (suprapubic) fullness and pain that worsens as the bladder fills (often relieved after urination)
  • Daytime urinary frequency, nocturia, and urinary urgency
  • Pain may radiate to the perineum, genitals, lower abdomen, lower lumbar region, or thighs
  • Symptoms may worsen with certain foods (caffeine, alcohol, spicy or acidic foods, etc.)

---

2) Treatment Methods

• Treatment goal: Symptom relief and improved quality of life rather than a cure
• Nonpharmacological treatment
  • Behavioral therapy: bladder training (gradually increasing the interval between urinations), scheduled urination, weight and exercise management
  • Dietary modification: avoiding bladder-irritating foods (caffeine, alcohol, chocolate, spicy or acidic foods, carbonated beverages, etc.)
  • Pelvic floor physical therapy: biofeedback, pelvic floor relaxation and retraining, and soft-tissue massage
• Pharmacological treatment
  • Oral medications: pentosan polysulfate, antidepressants (such as tricyclic antidepressants or SNRIs for pain control), antihistamines, low-dose steroids or immunosuppressants (selectively), anticholinergics or beta-3 agonists (to control accompanying urinary frequency and urgency), and alpha-blockers (when urinary retention or voiding dysfunction is present)
    • Medication-specific precautions: Although rare, retinopathy (fundus changes) has been reported with long-term use of pentosan polysulfate, so ophthalmologic follow-up should be considered.
  • Intravesical treatment (bladder instillation): instillation of medications aimed at restoring the mucosa and reducing inflammation (e.g., hyaluronic acid, DMSO, etc.) — repeated treatment over multiple sessions is necessary
• Procedures and surgical treatment
  • Bladder hydrodistension: may provide short-term symptom improvement in patients without Hunner lesions
  • Excision or electrocauterization of Hunner lesions (transurethral resection): effective for symptom improvement when Hunner lesions are present, but recurrence is possible
  • Intravesical botulinum toxin injection: for controlling detrusor overactivity and pain, but there is a risk of urinary retention
  • Neuromodulation (sacral neuromodulation), nerve blocks, and other treatments (for chronic pain control)
  • Major surgery (bladder augmentation, cystectomy with urinary diversion, etc.) is an extremely limited last-resort treatment
  • Experimental treatments: stem cells and others (currently at the research stage)
• Considerations when selecting treatment
  • The approach varies depending on the type of symptoms (whether Hunner lesions are present and whether pain or urinary frequency is predominant).
  • Treatment response varies greatly among individuals, and repeated combination treatment may be necessary.
• Precautions for this disease (complications and self-care considerations)
  • The chronic course may reduce quality of life and cause depression or anxiety.
  • Persistent voiding dysfunction and reduced sexual function may occur due to decreased bladder capacity.
  • There is a risk of temporary urinary retention or infection caused by medications (e.g., botulinum toxin).
  • Surgical treatment may involve a recovery period and complications (infection, fistula, etc.).

---

3) Checklist Before an Outpatient Visit (Including Preparation Items and Sample Questions)

• Items/documents to bring
  • A list of all currently used medications and supplements (including doses and times of administration)
  • Previous test results (urinalysis and urine cultures, cystoscopy findings, pelvic or abdominal imaging, and previous pathology reports)
  • A symptom diary (most recent 1–2 weeks): bladder diary (time of urination, urine volume, number of nighttime urinations), pain scores (0–10), and triggers (food, stress, menstruation, etc.)
  • Records of previous treatments (medications, bladder instillation, surgery, neuromodulation, etc.), including their effects and side effects
• Information to tell the healthcare provider in advance during an outpatient visit
  • Symptoms suggestive of an acute urinary tract infection (fever, a sudden increase in hematuria, foul odor or pyuria, etc.)
  • Recent changes in pregnancy status, contraception, or sexual activity
• Sample questions (including questions patients may prepare to ask their doctor during the visit)
  • Refer to the “General Sample Questions to Ask Your Doctor” and “Disease-Specific Sample Questions” sections below

---

4) General Sample Questions to Ask Your Doctor

• “What benefits can I expect from this medication (or treatment), and what side effects are expected?”
• “After starting treatment, how long will it take before I can expect improvement?”
• “What is the most appropriate first-line treatment for my symptoms? What is the priority between medication and nonpharmacological treatment?”
• “If the treatment is not effective, what is the next step (procedure/surgery), and what are the risks?”
• “What lifestyle changes are essential, and what self-care methods may help relieve my symptoms?”
• “Would I benefit from support or counseling for psychological effects such as insomnia, depression, or anxiety?”

---

5) Disease-Specific Sample Questions

• “What tests are needed to determine whether Hunner lesions were present on cystoscopy, and how do treatment options differ depending on whether they are present?”
• “If pentosan polysulfate (or a specific intravesical medication) is taken long term (or repeatedly instilled), what monitoring is needed for safety concerns, such as ophthalmologic risks and physical complications?”
• Additional (optional): “I am concerned about the possibility of urinary retention after a botulinum toxin injection. How should urinary retention be managed if it occurs?”

---

Note: This material is general medical information. Final decisions regarding diagnosis and treatment should be made in consultation with the treating healthcare provider.